Acuta Capital Partners, LLC Applied Therapeutics Inc. Transaction History

Acuta Capital Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.25 - $7.4 $600,525 - $1.98 Million	266,900 Added 50.83%	792,000 $5.39 Million
Q4 2023 Feb 14, 2024	BUY	$1.84 - $3.35 $966,184 - $1.76 Million	525,100 New	525,100 $1.76 Million
Q3 2020 Nov 16, 2020	SELL	$19.43 - $35.36 $3.54 Million - $6.44 Million	-182,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.41 - $51.23 $2.35 Million - $4.1 Million	80,000 Added 78.43%	182,000 $6.58 Million
Q1 2020 May 15, 2020	SELL	$19.54 - $55.47 $898,840 - $2.55 Million	-46,000 Reduced 31.08%	102,000 $3.33 Million
Q4 2019 Feb 14, 2020	BUY	$10.16 - $28.14 $660,400 - $1.83 Million	65,000 Added 78.31%	148,000 $4.04 Million
Q3 2019 Nov 14, 2019	BUY	$8.08 - $10.99 $670,640 - $912,170	83,000 New	83,000 $912,000

140

112M

1.68M

1.91M

Ticker APLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,700
Market Cap $34.1M
Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.